Surgical site infections (SSIs) are a significant healthcare system burden​

SSIs prolong healing and hospital length of stay, increase costs and reduce patients’ quality of life.30

Each SSI may have the following impact​

9.7 days

Average extended hospital length of stay.30,31

>$20,000 USD

Increase in the cost of hospitalization.30,31

2-11 fold

Increased risk of mortality.30

Myriad has a low rate of device-related complications across a range of complex, acute and chronic wounds

Myriad published SSI and median application rates

ReferenceCDC Contamination scoreSample sizeSSI rateMedian product applications 
Grade II (8/230 cases)
Grade III (112/230 cases)
1300% 1.0
Grade II (8/13 cases)
Grade III (5/13 cases)
130% 1.0
Grade II30% 1.0
Grade IV500% 1.0
Grade III60% 1.0
Grade III80% 1.0
Grade II (5/9 cases)
Grade III (4/9 cases)
911% 1.0
Grade III140% 1.0
Grade II (4/6 cases)
Grade III (2/6 cases)
60% 1.0

Myriad may help reduce the overall cost of care

Enables earlier intervention

Despite the presence of contamination.1-4

Reduces the frequency of NPWT dressing changes

By working synergistically with NPWT.2,3

Minimal complications

Low infection rate and graft loss, even in contaminated defects1-7,11,26

A versatile portfolio for soft tissue repair

Myriad Matrix™

Multiple layers of AROA ECM to enable regeneration of organized, functional tissue.

Myriad Morcells™

A conformable graft of morselized Myriad. Ideal for irregular, tunneled or undermined wounds.

Myriad Morcells Fine™

A finer particulate of Myriad Morcells. Ideal for irregular, tunneled or undermined wounds.

AROA ECM™

Our foundation technology

Derived from ovine forestomach, the AROA ECM technology is a patented platform for our soft tissue repair and reconstruction portfolio. It regenerates functional tissue, enabling clinicians to achieve more for patients.